Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.
Adult pneumonia
Indirect PCV impact
Mongolia
Nasopharyngeal carriage
Pneumococcal conjugate vaccine
Streptococcus pneumoniae
Surveillance
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
23 09 2021
23 09 2021
Historique:
received:
08
02
2021
accepted:
13
09
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colonisation with vaccine-type serotypes. The resulting decrease in transmission of vaccine serotypes leads to large indirect effects. There are limited data from developing countries demonstrating the impact of childhood PCV immunisation on adult pneumonia. There are also insufficient data available on the burden and severity of all-cause pneumonia and respiratory syncytial virus (RSV) in adults from low resource countries. There is currently no recommendation for adult pneumococcal vaccination with either pneumococcal polysaccharide vaccine or PCVs in Mongolia. We describe the protocol developed to evaluate the association between childhood 13-valent PCV (PCV13) vaccination and trends in adult pneumonia. PCV13 was introduced into the routine childhood immunisation schedule in Mongolia in a phased manner from 2016. In March 2019 we initiated active hospital-based surveillance for adult pneumonia, with the primary objective of evaluating trends in severe hospitalised clinical pneumonia incidence in adults 18 years and older in four districts of Ulaanbaatar. Secondary objectives include measuring the association between PCV13 introduction and trends in all clinically-defined pneumonia, radiologically-confirmed pneumonia, nasopharyngeal carriage of S. pneumoniae and pneumonia associated with RSV or influenza. Clinical questionnaires, nasopharyngeal swabs, urine samples and chest radiographs were collected from enrolled patients. Retrospective administrative and clinical data were collected for all respiratory disease-related admissions from January 2015 to February 2019. Establishing a robust adult surveillance system may be an important component of monitoring the indirect impact of PCVs within a country. Monitoring indirect impact of childhood PCV13 vaccination on adult pneumonia provides additional data on the full public health impact of the vaccine, which has implications for vaccine efficiency and cost-effectiveness. Adult surveillance in Mongolia will contribute to the limited evidence available on the burden of pneumococcal pneumonia among adults in low- and middle-income countries, particularly in the Asia-Pacific region. In addition, it is one of the few examples of implementing prospective, population-based pneumonia surveillance to evaluate the indirect impact of PCVs in a resource-limited setting.
Sections du résumé
BACKGROUND
Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colonisation with vaccine-type serotypes. The resulting decrease in transmission of vaccine serotypes leads to large indirect effects. There are limited data from developing countries demonstrating the impact of childhood PCV immunisation on adult pneumonia. There are also insufficient data available on the burden and severity of all-cause pneumonia and respiratory syncytial virus (RSV) in adults from low resource countries. There is currently no recommendation for adult pneumococcal vaccination with either pneumococcal polysaccharide vaccine or PCVs in Mongolia. We describe the protocol developed to evaluate the association between childhood 13-valent PCV (PCV13) vaccination and trends in adult pneumonia.
METHODS
PCV13 was introduced into the routine childhood immunisation schedule in Mongolia in a phased manner from 2016. In March 2019 we initiated active hospital-based surveillance for adult pneumonia, with the primary objective of evaluating trends in severe hospitalised clinical pneumonia incidence in adults 18 years and older in four districts of Ulaanbaatar. Secondary objectives include measuring the association between PCV13 introduction and trends in all clinically-defined pneumonia, radiologically-confirmed pneumonia, nasopharyngeal carriage of S. pneumoniae and pneumonia associated with RSV or influenza. Clinical questionnaires, nasopharyngeal swabs, urine samples and chest radiographs were collected from enrolled patients. Retrospective administrative and clinical data were collected for all respiratory disease-related admissions from January 2015 to February 2019.
DISCUSSION
Establishing a robust adult surveillance system may be an important component of monitoring the indirect impact of PCVs within a country. Monitoring indirect impact of childhood PCV13 vaccination on adult pneumonia provides additional data on the full public health impact of the vaccine, which has implications for vaccine efficiency and cost-effectiveness. Adult surveillance in Mongolia will contribute to the limited evidence available on the burden of pneumococcal pneumonia among adults in low- and middle-income countries, particularly in the Asia-Pacific region. In addition, it is one of the few examples of implementing prospective, population-based pneumonia surveillance to evaluate the indirect impact of PCVs in a resource-limited setting.
Identifiants
pubmed: 34556065
doi: 10.1186/s12889-021-11776-8
pii: 10.1186/s12889-021-11776-8
pmc: PMC8460191
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1731Informations de copyright
© 2021. The Author(s).
Références
PLoS One. 2020 Apr 1;15(4):e0231041
pubmed: 32236150
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
EClinicalMedicine. 2019 Jan 02;6:42-50
pubmed: 31193709
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Nat Med. 2004 Aug;10(8):811-3
pubmed: 15247911
PLoS One. 2019 Oct 29;14(10):e0224392
pubmed: 31661527
Clin Infect Dis. 2018 Mar 19;66(7):1075-1085
pubmed: 29069315
Thorac Cancer. 2020 Mar;11(3):505-510
pubmed: 31975505
Vaccine. 2013 Dec 16;31(52):6232-8
pubmed: 24176490
BMC Public Health. 2019 Mar 21;19(1):333
pubmed: 30898094
BMC Infect Dis. 2010 Oct 23;10:304
pubmed: 20969800
Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):197-201
pubmed: 18830727
Infect Chemother. 2016 Dec;48(4):257-266
pubmed: 28032483
J Clin Microbiol. 2007 Aug;45(8):2460-6
pubmed: 17537936
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Clin Ther. 2008 Feb;30(2):341-57
pubmed: 18343273
Thorax. 2020 Jan;75(1):38-49
pubmed: 31594801
Vaccine. 2019 May 31;37(25):3352-3361
pubmed: 31072732
Infect Chemother. 2013 Dec;45(4):351-66
pubmed: 24475349
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Vaccine. 2017 May 19;35(22):2882-2891
pubmed: 28449971
J Virol Methods. 2012 Jan;179(1):250-5
pubmed: 22119628
Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):157-160
pubmed: 30353485
Vaccine. 2013 Dec 17;32(1):165-79
pubmed: 24331112
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
Clin Infect Dis. 2020 Dec 3;71(9):e430-e438
pubmed: 32072165
Clin Vaccine Immunol. 2012 Aug;19(8):1131-41
pubmed: 22675155
Vaccine. 2013 Dec 17;32(1):133-45
pubmed: 23684824
Vaccine. 2019 Jul 9;37(30):4068-4075
pubmed: 31174939
Bull World Health Organ. 2005 May;83(5):353-9
pubmed: 15976876
PLoS Med. 2015 Jan 06;12(1):e1001776
pubmed: 25562317
Thorax. 2008 Jan;63(1):42-8
pubmed: 17573440
J Infect Dis. 2017 Dec 5;216(10):1187-1195
pubmed: 29040627
BMC Infect Dis. 2010 Feb 10;10:22
pubmed: 20146815
Clin Infect Dis. 2019 May 30;68(12):2117-2119
pubmed: 30462172
Lancet Infect Dis. 2015 Apr;15(4):405-14
pubmed: 25701560
Expert Rev Vaccines. 2012 Jul;11(7):841-55
pubmed: 22913260
Influenza Other Respir Viruses. 2014 Sep;8(5):530-7
pubmed: 25043147
Clin Infect Dis. 2019 Nov 27;69(12):2177-2184
pubmed: 30785189
PLoS Med. 2015 Nov 17;12(11):e1001903; discussion e1001903
pubmed: 26575033
PLoS One. 2013;8(4):e60273
pubmed: 23565216
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Epidemiology. 2019 Nov;30(6):838-844
pubmed: 31430265
Clin Microbiol Rev. 2006 Jul;19(3):571-82
pubmed: 16847087
Chest. 2008 Dec;134(6):1141-1148
pubmed: 18689592
Pediatr Infect Dis J. 2006 Jun;25(6):494-501
pubmed: 16732146
J Glob Health. 2019 Dec;9(2):020431
pubmed: 31893034
J Infect Dis. 2019 Oct 22;220(11):1771-1779
pubmed: 30923799
PLoS One. 2019 Sep 11;14(9):e0222423
pubmed: 31509593